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Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing severe
outbreaks in humans and livestock in sub-Saharan Africa and the Arabian Peninsula.
Human infections are characterized by fever, sometimes leading to encephalitis, retinitis,
hemorrhagic fever, and occasionally death. There are currently no fully licensed vaccines
or effective therapies for human use. Gene silencing mediated by double-stranded
short interfering RNA (siRNA) is a sequence-specific, highly conserved mechanism in
eukaryotes, which serves as an antiviral defense mechanism. Here, we demonstrate
that siRNA duplexes directed against the RVFV nucleoprotein can effectively inhibit
RVFV replication in human (MRC5 cells) and African green monkey cells (Vero E6
cells). Using these cells, we demonstrate that individual or complex siRNAs, targeting
the RVFV nucleoprotein gene completely abrogate viral protein expression and prevent
degradation of the host innate antiviral factor, protein kinase R (PKR). Importantly, pre-
treatment of cells with the nucleoprotein-specific siRNAs markedly reduces the virus
titer. The antiviral effect of the siRNAs was not attributable to interferon or the interferon
response effector molecule, PKR. Thus, the antiviral activity of RVFV nucleoprotein-
specific siRNAs may provide novel therapeutic strategy against RVFV infections in
animals and humans.
Keywords: short interfering RNA, RNA interference, antiviral, Rift Valley fever virus, nucleoprotein, protein
kinase R
INTRODUCTION
Rift Valley fever virus (RVFV) is a mosquito-borne, zoonotic pathogen that causes Rift Valley
fever (RVF) in humans and livestock in sub-Saharan Africa and the Arabian Peninsula (Flick and
Bouloy, 2005). The virus is classified as a Category A pathogen and a select agent by the National
Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). For decades,
RVFV has been associated with epizootics in animals and epidemics in humans in Africa and
since 2000, also in the Arabian Peninsula. For example, in 1987, an epidemic of RVF occurred
in the Senegal River basin of southern Mauritania and adjacent northern Senegal resulting in 232
human deaths in Mauritania alone, including high rates of abortion in sheep and goats (Jouan et al.,
1989). In 2000, for the first time, a RVF outbreak occurred in Saudi Arabia and Yemen resulting
in 245 human deaths and the loss of thousands of sheep and goats (Shoemaker et al., 2002).
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Apparently, the first known human fatality due to RVF was
recorded in 1934 in a laboratory worker in the USA soon
after the initial isolation of the virus in 1931 (Schwentker and
Rivers, 1934). Human RVFV infections are characterized by fever,
which may progress to encephalitis, retinitis, hemorrhagic fever,
and death (Ikegami and Makino, 2011; LaBeaud et al., 2015).
There are no therapies approved for human use. Significant
efforts have been directed at vaccine development including
development of 1NSs-1NSm recombinant RVFV (Bird et al.,
2011) and recombinant RVFV Gn/Gc (Faburay et al., 2016)
vaccines. Although both vaccines have shown to be safe and
efficacious in animals, neither is approved for human use;
and in the case 1NSs-1NSm recombinant RVFV, which is a
modified live attenuated virus, there are concerns about its use
in non-endemic areas. Meanwhile, higher human case fatality
rates, ranging from 20% to even 50%, have been reported
in recent outbreaks in Africa (Nguku et al., 2010; Heald,
2012; Nanyingi et al., 2015). With the potential of spread
of RVFV to non-endemic areas, as well as its potential as a
bioterror agent (Mandell and Flick, 2010), the development
of effective countermeasures against this pathogen is urgently
needed.
RNA interference is recognized as one of the most promising
platform for the development of therapeutics against viral
pathogens. It represents an endogenous mechanism employed
by many organisms used to silence the expression of genes that
control various events in a cell (Elbashir et al., 2001) and also
provides antiviral activity (Gitlin et al., 2002). Its high efficiency
(Bertrand et al., 2002), specificity (Brummelkamp et al., 2002;
Xia et al., 2004), and broad applicability could be harnessed to
develop a powerful new therapeutic approach for many infections
(Haasnoot and Berkhout, 2006; Medarova et al., 2007). The
search for novel antiviral agents has led to short interfering RNAs
(siRNAs), which act via sequence-selective inhibition of viral
replication (Haasnoot et al., 2003; Haasnoot and Berkhout, 2006).
Rift Valley fever virus contains single-stranded, negative,
segmented RNA genome that encodes four structural proteins,
the nucleoprotein (N), the glycoproteins Gn and Gc, and the
L polymerase; two non-structural proteins, NSs and NSm, and
a 78-kDa protein of unknown function (Gerrard and Nichol,
2007; Won et al., 2007). Although both NSs and NSm are
dispensable for RVFV replication in vitro and in vivo (Ikegami
et al., 2006; Gerrard et al., 2007; Bird et al., 2008), both proteins
play a critical role in viral pathogenesis. NSm acts as an anti-
apoptotic protein (Won et al., 2007), whereas NSs, the major
viral virulence factor, inhibits host innate immune response
(Bouloy et al., 2001) through generalized downregulation of RNA
transcription, including suppression of interferon-β (IFN-β)
(Billecocq et al., 2004; Le May et al., 2004, 2008) and degradation
of protein kinase R (PKR) (Habjan et al., 2009; Ikegami et al.,
2009a). PKR is a host-encoded pattern recognition receptor
with innate antiviral activity (Ikegami et al., 2009b). The RVFV
N protein is associated with the viral genomic RNA and
together with the L protein makes up the ribonucleoprotein
(RNP) complex, which is responsible for RNA transcription and
replication of the RVFV genome. Both genes are highly conserved
(Ikegami, 2012). Therefore, the N and L proteins represent
ideal targets for developing antiviral interventions using siRNAs.
We therefore hypothesized that posttranscriptional silencing of
the RVFV N and L genes will have significant effects RVFV
replication. Using the attenuated RVFV strain MP12 (Caplen
et al., 1985), classified as a BSL-2 pathogen, we assessed the effect
of posttranscriptional silencing of the N and L polymerase genes
on RVFV replication.
MATERIALS AND METHODS
Cells, Virus, and Virus Titrations
Human lung fibroblast cells (MRC-5; ATCC, Manassas, VA,
USA) and African Green Monkey kidney cells (Vero E6
cells) were propagated in modified Eagle medium (MEM)
supplemented with 10% fetal bovine serum (FBS) at 37◦C with
5% CO2. MP12 is an attenuated RVFV strain (Caplen et al.,
1985) and was used as the RVFV strain for all cell infections. The
MP12 virus carries a functional virulence gene, NSs, and sequence
alignment of its nucleoprotein gene shows 100% identity to
the parent wild-type RVFV strain, ZH548 (unpublished data).
MP12 virus titers were quantified in Vero E6 cells using standard
protocols (Faburay et al., 2014) and titers were expressed as
plaque forming units per ml (pfu/ml).
Recombinant Plasmid Constructs
The plasmid pAcGFP (Takara Clontech, Mountain View, CA,
USA) was linearized with the restriction enzyme HindIII
(New England Biolabs, Ipswich, MA, USA). RVFV N coding
sequence, based on the RVFV strain ZH548, was amplified
from the donor plasmid, pFastBacNP (Faburay et al., 2013)
using gene-specific primers. The primers were designed using
the primer design software (Takara Clontech) that allowed
directional cloning of the PCR amplicon into a linearized
pAcGFP using the In-Fusion Cloning Plus kit (Takara Clontech).
The primers used were JAR121F 5′-TCTCGAGCTCAAGCTT
ATGGACAACTATCAAGACCTTGCGATCC-3′ and JAR122R
5′-GCAGAATTCGAAGCTTGGCTGCTGTCTTGTAAGCCTG
AGCG-3′ (vector sequences are underlined). PCR was
performed using proof-reading DNA polymerase, Pfx50
DNA polymerase (Life Technologies, Carlsbad, CA, USA) using
reaction conditions as specified by the manufacturer. The PCR
amplicons were purified using a PCR purification kit (Qiagen,
Valencia, CA, USA) and cloned into pAcGFP according to the
manufacturer’s instructions to create the recombinant expression
vector, pAcGFP-N. The RVFV N sequence was cloned without
the stop codon and in-frame with the coding sequence of
the Green Fluorescent protein (GFP) to allow expression of a
chimeric RVFV N-GFP fusion protein. The cloning reaction was
transformed into chemically competent E. coli Max Efficiency
(Life Technologies, Carlsbad, CA, USA) and transformants were
selected on Luria-Bertani (LB) agar plates containing kanamycin
(30 µg/ml). Recombinant plasmids were purified from overnight
E. coli cultures using a Miniprep kit (Qiagen, Valencia, CA,
USA). The presence and integrity of RVFV N-GFP chimeric
sequences were determined by restriction enzyme analysis and
DNA sequencing.
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Design and In vitro Screening of siRNAs
in Cotransfection Experiments
Several siRNA duplexes targeting different loci within the RVFV
N (si46N, si252N, si605N, si476N) and L polymerase (si5849L)
mRNA transcripts were designed using a conventional siRNA
design algorithm (Table 1). Additionally, siRNAs targeted at
GFP (si475GFP) and Renilla luciferase (si689RL) genes were
constructed for use as positive knockdown and scrambled
negative controls, respectively (Table 1). The Basic Local
Alignment Search Tool (National Center for Biotechnology
Information, Bethesda, MD, USA) was used to exclude siRNAs
with sequence homology to any human reference mRNAs
of 16 or more contiguous bases within the core duplex.
The siRNA duplexes were synthesized by Integrated DNA
Technologies (Coral Ville, IA, USA). Screening of siRNAs to
assess knockdown of gene expression was performed using a
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA)
cotransfection protocol. Briefly, individual siRNA duplexes
were reconstituted in DNase and RNase-free water to a stock
concentration of 20 or 40 µM. For transfection, MRC5 cells
were seeded and grown overnight in 12-well plates to 80–90%
confluency. Thereafter, 150 ng of each plasmid, pAcGFP-N or
intact pAcGFP control plasmid, was mixed with 10 pmol of
the respective RVFV N-specific siRNAs, si46N/si605N mixed, or
individually, si475GFP (GFP positive control) or si689RL (Renilla
luciferase negative scrambled control) in Opti-MEM reduced
serum medium (Life Technologies, Carlsbad, CA, USA). After
20 min incubation, the reaction mixture was added dropwise
to MRC5 cells in Opti-MEM reduced serum medium. After 6 h
post transfection, the reduced serum medium was replaced with
complete cell culture medium and cells incubated in a humidified
incubator at 37◦C with 5% CO2 for 48 h. Knockdown of target
gene expression was assessed by fluorescent microscopy (Nikon,
Eclipse TE2000-S) and Western blot analysis.
Western Blot
Western blot analysis was performed to assess siRNA-mediated
knockdown of target protein expression (N and GFP). Also,
inhibition of cellular PKR (a constitutively expressed host
antiviral innate immune response factor) expression was assessed
as a function of intracellular RVFV replication. Beta actin
expression was used as a loading control. Briefly, MRC5 and Vero
cells were washed with PBS pH 7.4 and the cells resuspended
in lysis buffer (PBS pH 7.4 containing 1% Triton X-100
and 1x Roche Complete Protease Inhibitor). Approximately,
5 µg of total protein lysate was resolved in 12% Bis-Tris
polyacrylamide gel (Life Technologies, Carlsbad, CA, USA).
The proteins were transferred by electroblotting onto PVDF
membranes according to standard protocols. After blocking for
1 hr in PBS pH 7.4 containing 0.1% Tween20 and 3% bovine
serum albumin, the blots were probed with either mouse anti-
RVFV N (R3-ID8; 1: 2,000) (BEI Resources, NIH, Manassas, VA,
USA), anti-GFP (1:300) (Santa Cruz Biotechnology, Dallas, TX,
USA), anti-PKR (1:200) or anti-beta actin (1:200; Santa Cruz
Biotechnology, Dallas, TX, USA) monoclonal antibodies for 1 hr.
The membranes were washed and then incubated for 1 hr with
goat anti-mouse-HRP conjugated secondary antibody (1:5,000)
(Santa Cruz Biotechnology, Dallas, TX, USA) and specific
reactivity was detected using enhanced chemiluminescent (ECL)
detection system (GE Healthcare, Buckinghamshire, UK).
Determination of siRNA Effects on RVFV
Protein Expression
Vero E6 cells were seeded overnight in 12-well plates at 1 × 106
cells per well so that they are 80–90% confluent the next day
at the time of transfection. On the day of transfection, the old
medium was replaced with fresh medium. Transfection mixtures
were prepared using RNAiMax reagent (Life Technologies,
Carlsbad, CA, USA) in Opti-MEM reduced serum medium
using 50 nM (final concentration) of each siRNA. This was
empirically determined to be an optimal siRNA concentration
that inhibits viral replication without noticeable effect on cell
viability (data not shown). To assess inhibition of RVFV
nucleoprotein expression in Vero cells, the following siRNAs
were tested in duplicate wells: (i) si605N/si46N/si252N/si476N,
(ii) si605N, (iii) si46N, (iv) si605N/si5849L, (v) si5849L, (vi)
si475GFP and (vii) si689RL (scrambled negative control). At
24 h post transfection, cells were infected with MP12 virus at
multiplicity of infection (MOI) of 2. After 1 h adsorption period,
the viral inoculum was removed and replaced with 1 ml complete
culture medium (MEM supplemented with 10% FBS), and the
cells incubated at 37◦C for 48 h. Cell lysates were prepared as
described above and analyzed by Western blot.
Determination of siRNA Effects on
Prevention of Protein Kinase R
Degradation
The RVFV MP12 carries a functional NSs gene, a major RVFV
virulence factor, responsible for inhibition of host innate immune
response including degradation of PKR (Billecocq et al., 2008;
Habjan et al., 2009; Ikegami et al., 2009a). Thus viral degradation
of cellular PKR was assessed as a parameter to detect RVFV
replication in human cells and its response to siRNA treatment.
MRC5 cells were seeded overnight in 12-well plates at 1 × 106
cells per well so that they are 80–90% confluent the next day at the
time of transfection. On the day of transfection, the old medium
was replaced with fresh medium. Transfection mixtures were
prepared with RNAiMax reagent (Life Technologies, Carlsbad,
CA, USA) in OptiMEM reduced serum medium to contain 50 nM
(final concentration) of each siRNA as described above. At 24 h
post transfection, cells were infected with MP12 virus at a MOI of
1. After 1 h adsorption period, the viral inoculum was removed
and replaced with 1 ml complete culture medium, and the cells
were incubated at 37◦C for 48 h. Cell lysates were prepared as
described above and analyzed for expression of PKR by Western
blot.
Determination siRNA Effects on RVFV
Replication
Quantitative RT-PCR
To assess siRNA inhibition of RVFV RNA replication, viral RNA
was extracted from the culture supernatants using Qiagen Viral
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TABLE 1 | Sequences of small interfering RNAs used for knockdown of target gene expression.
siRNA ID Sense Antisense Target gene
si46N ggaccgcaaugagauugaauu uucaaucucauugcgguccuu RVFV nucleoprotein
si605N gcagugaauagcaacuuuauu uaaaguugcuauucacugcuu RVFV nucleoprotein
si252N cucucaucaacaaguauaauu uuauacuuguugaugagaguu RVFV nucleoprotein
si476N gacuaucuaagggcaauauuu auauugcccuuagauagucuu RVFV nucleoprotein
si5849L gucggaucuauguucucauuu augagaacauagauccgacuu RVFV RNA polymerase
si475GFP gaauggcaucaaggugaacuu guucaccuugaugccauucuu Green fluorescent protein
si689RL ccugacguuguacaaauuguu caauuuguacaacgucagguu Renilla luciferase
RNA extraction kit (Qiagen, Valencia, CA, USA). Briefly, Vero E6
cells were seeded overnight at 1 × 106 cells per well so that they
are 80–90% confluent the next day at the time of transfection.
Wells were transfected in duplicate with si605N, si46N,
si252N, si476N, and siPooledN (si605N/si46N/si252N/si46N) as
described above. At 48 h post transfection, cells were infected
with MP12 virus at MOI of 0.1. After 1 h adsorption, the virus
inoculum was removed and replaced with complete cell culture
medium. At 24 h post infection, supernatants were collected
and aliquots were used to determine viral RNA replication
by qRT-PCR and virus replication by plaque assay (described
below). Briefly, a quantitative RT-PCR (qRT-PCR) targeting the
L segment was performed (Faburay, unpublished). A SuperScript
III One-step RT-PCR protocol with forward primer BJF 5′-CTT
AGC TGA CAA GAC TGA CAG AC-3′ and reverse primer BJR
5′-GTA CCT ATA AAC CAT CTC CTC TGC-3′ and Taqman
Probe BJP FAM 5′-AGG GGA GAT GAA AGA GGT GCA
TTC CAG GCT-3′-IABKFQ (Iowa Black) was used. The assay
was performed using the following reaction conditions: 50◦C
for 15 min, and then 35 times 95◦C for 2 min and 60◦C for
15 s, using the CFX96 Real-Time System (Bio-Rad, Hercules, CA,
USA).
Flow Cytometry
To further assess the effect of siRNAs on viral replication,
flow cytometry analysis was performed. Briefly, cells were
seeded and transfected with the various siRNAs (si605N, si46N,
si252N, si476N, and siPooledN (si605N/si46N/si252N/si46N)
as described above. siRNA untreated but virus-infected (virus
control) cells, and untreated, non-infected cells were included as
relevant controls. At 48 h post transfection, cells were infected
with MP12 virus at a MOI of 0.1. After 1 h adsorption, the
virus inoculum was removed and replaced with complete cell
culture medium. At 24 h post infection, cells were harvested
using Accutase (MP Biomedicals, Solon, OH, USA) and were
used for flow cytometry analysis. Briefly, cells were pelleted
by centrifugation at 5,000 × g for 10 min and then fixed
in 4% paraformaldehyde for 30 min. The cell pellets were
resuspended in PBS pH 7.4 containing 10 mM glycine and
incubated overnight at 4◦C. Thereafter, the cells were stained
by incubating with mouse anti-RVFV N monoclonal antibody
(R3-4D8) (1:100 dilution; BEI Resources, NIH, Manassas, VA,
USA) in permeabilized buffer (PBS, 7.4 containing 0.1% saponin,
20 mm EDTA, 0.02% sodium azide, 2% FBS) for 1 h at 4◦C.
Following two washing steps, cells were incubated with Alexa
Fluor-488 conjugated goat-antimouse IgG antibody (5 µg/ml
final concentration) (Molecular Probes, Thermo Fisher Scientific,
Eugene, OR, USA) for 30 min at 4◦C. Cells were analyzed
by flow cytometry on BD LSR Fortessa X-20 using a 525/50
Band Pass Filter for the FITC detector off a 488 nm blue
laser.
Virus Titration by Plaque Assay
Virus titrations were performed in Vero E6 cells by plaque assay
according to previously described protocols (Faburay et al., 2014)
using supernatants collected from the experiments described
above for qRT-PCR. Briefly, 10-fold serial dilutions of the
supernatants from the various siRNA treatments were made and
used to infect monolayers of overnight cultures of Vero E6 cells
in 6-well plates. After 1 h adsorption of the virus at 37◦C and
5% CO2, the viral inoculum was removed and the monolayer
overlaid with 0.9% agarose. The plates were incubated at 37◦C
and 5% CO2 for 4 days. After fixing with 10% formalin for 3 h
(Faburay et al., 2014), monolayers were stained with 0.5% crystal
violet and plaques counted and quantified according to standard
protocol. Titers were expressed as plaque forming units per ml
(pfu/ml).
Statistical Analysis
Differences in response values between siRNA treated and
untreated controls were analyzed for statistical significance using
Graphpad Prism 6. An unpaired t-test was used to compare
mean response values between various siRNA treatments, as
well as compare the mean values of the siRNA treatments and
the controls. A P-value of ≤0.05 was considered statistically
significant.
RESULTS
Knockdown of GFP and RVFV N Protein
Expression Using siRNAs in pAcGFP
Transfected MRC-5 Cells
Knockdown of the expression of the RVFV N-GFP fusion
protein encoded by the plasmid pAcGFP-N was performed in
MRC-5 cells using the RVFV nucleoprotein-specific siRNAs
si605N/si46N. Co-transfection of the pAcGFP-N plasmid with
the siRNAs si605N/si46N resulted in inhibition of N-GFP
fusion protein expression as demonstrated by the absence of
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FIGURE 1 | siRNA-knockdown of exogenous gene expression in MRC5 cells. (A) Fluorescence analysis shows inhibition of pAcGFP-N and pAcGFP plasmid
expression. RVF N-specific si605N/si46N cotransfection (+) inhibited expression of GFP-N fusion protein in contrast to the untreated control (−); GFP-specific
si475GFP cotransfection (+) inhibited expression of the green fluorescent protein. si689RL, the scrambled non-specific Renilla luciferase-siRNA, shows no inhibition
of GFP-N protein expression. (B) Western blot analysis of siRNA knockdown of exogenous protein expression. Lane 1: expression of GFP (without siRNA treatment;
arrow shows an estimated 27 kDa molecular weight protein); lane 2: knockdown of GFP expression with si475GFP; lane 3: knockdown of GFP-N fusion protein with
si605N/si46N; lane 4: expression of GFP-N fusion protein (without siRNA treatment; arrow shows an estimated 54 kDa molecular weight protein); lane 5: cells only
control. β-actin serves as loading control.
specific GFP fluorescence (Figure 1A) and the fusion protein-
specific band in Western blot analysis (Figure 1B). Treatment
with the positive control siRNA, si475GFP, targeting the GFP
gene, abrogated expression or fluorescence of the GFP-N fusion
fusion protein (Figures 1A,B). In contrast, GFP fluorescence
was observed in all mock-treated cells transfected with the
recombinant plasmids pAcGFP-N or pAcGFP (Figure 1A).
Treatment of the MRC5 cells with the scrambled negative control
siRNA, si689RL, did not have any effect on fusion protein
expression as demonstrated by clear expression of the N-GFP
fusion protein (Figure 1A).
Inhibition of RVFV Nucleoprotein
Expression in MP12-Infected Vero Cells
Viral nucleoprotein expression in Vero E6 cells infected
with MP12 RVFV was completely abrogated by all the
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FIGURE 2 | RVFV siRNA-specific inhibition of viral nucleoprotein
expression in Vero E6 cells. Numbers above the panel depict various
siRNA treatments. Lane 1: si605N/si46N/si252N/si476N (siPooledN; RVFV
N-specific siRNAs); lane 2: si605N; lane 3: si46N; lane 4: si605N/si5849L;
lane 5: si5849L (RVFV L-segment specific siRNA); lane 6: si475GFP
(GFP-specific siRNA); lane 7: si689RL (Renilla luciferase-siRNA); lane 8:
untreated virus control; lane 9: uninfected cell only control; lane 10:
recombinant RVFV N protein control (∼30 kDa). Lanes 5, 6, 7, 8: show
expression of viral nucleoprotein (∼27 kDa). β-actin serves as loading control.
M, molecular weight marker.
RVFV N-specific siRNA treatments (lanes 1–4; Figure 2).
Specifically, pretreatment with a complex pool of siRNAs,
si605N/46N/252N/476N (siPooledN), si605N/si5849L or with
individual siRNA duplexes, si605N or si46N, completely
abrogated RVFV nucleoprotein expression following RVFV
infection. However, when cells were treated with siRNA si5849L
alone, which targets the viral L polymerase gene, no inhibition
of viral nucleoprotein expression was observed (Figure 2).
Similarly, pretreatment with non-specific scrambled siRNAs,
si475GFP, and si689RL, specific to transcripts of GFP and Renilla
luciferase, respectively, did not inhibit nucleoprotein expression
(Figure 2). Untreated MP12 infected cells showed distinct
nucleoprotein expression (Figure 2, lane 8). Uninfected and
siRNA-untreated cells controls did not show any nucleoprotein
expression (Figure 2, lane 9).
siRNA Treatment Prevents Degradation
of Protein Kinase R
Protein kinase R is a host-encoded interferon response effector
molecule that is subjected to degradation by the RVFV non-
structural protein NSs upon viral infection; this allows NSs to
suppress the host innate immune responses (Habjan et al., 2009).
The NSs coding sequence of RVFV strain MP12 is functionally
active as demonstrated by degradation of constitutively
expressed PKR in MP12-infected MRC5 cells (data not shown).
Thus, expression of PKR in MP12-infected MRC-5 cells treated
with RVFV N-specific siRNA should result in inhibition of
RVFV replication. Treatment with RVFV-specific siRNAs,
si605N/si46N/si252N/si476N (siPooledN), si605N/si5849L,
si605N or si46N, significantly inhibited degradation of PKR
in MP12- infected cells as demonstrated by detection of
the PKR-specific 68 kDa protein in Western blot analysis
(Figure 3). When si5849L, targeting the L polymerase gene,
was used, degradation and loss of PKR in MP12-infected cells
FIGURE 3 | Analysis of degradation of protein kinase R (PKR) in human
cells (MRC5) in response to RVFV replication. Numbers above the panel
depict various siRNA treatments. Lane 1: si605N/si46N/si252N/si476N
(siPooledN; RVFV N-specific siRNAs); lane 2: si605N; lane 3: si46N; lane 4:
si605N/si5849L; lane 5: si5849L (RVFV L-segment specific siRNA); lane 6:
si475GFP (GFP-specific siRNA); lane 7: si689RL (Renilla luciferase-specific
siRNA); lane 8: virus control (untreated); lane 9: uninfected cell only control.
Lanes 1, 2, 3, 4: show inhibition of PKR degradation due to RVFV-specific
siRNA treatment as indicated by detection of a 68 kDa specific cellular
protein. β-actin serves as loading control. M, molecular weight marker.
was observed. Similarly, treatment with non-specific siRNAs,
si475GFP, and si689RL, did not protect PKR from NSs-mediated
degradation (Figure 3).
siRNA Treatment Inhibits RVFV MP12
Replication
As shown above, RVFV N-specific siRNAs inhibit viral
nucleoprotein expression and prevent degradation host encoded
PKR. Here, their potential to inhibit viral replication was assessed
using qRT-PCR, flow cytometry and virus plaque assays. qRT-
PCR cycle threshold (Ct) values obtained in cells infected
with MP12 and treated with RVFV N-specific siRNAs were
significantly higher when compared to the untreated control cells
(P < 0.05) (Figure 4A). The amount of viral RNA produced
after treatment with N-specific siRNAs, individually or as pooled
complex, were at least 3 logs lower when compared to the
untreated MP12-infected control (P < 0.05). Specifically, si605
and si46 displayed the highest fold reductions in virus replication
of log10 3.74 and 3.63, respectively (Figure 4B). Flow cytometry
analysis confirmed these results. Only background fluorescence
was detectable in all N-specific siRNA treatments indicating
effective inhibition of MP12 replication. In contrast, a strong
positive fluorescence was detected in the untreated virus-infected
control cells (Figure 5). Quantitation by plaque assay confirmed
the above results. Production of viral progeny was significantly
inhibited by the N-specific siRNA treatments when compared
to the untreated infected control (P < 0.05) (Figure 6A).
Meanwhile, si605N, si46N, and siPooledN exhibited stronger
inhibition than si252N and si476N (Figure 6A). The magnitude
of inhibition of virus replication was demonstrated by the absence
of viral plaques in a 104 dilution of culture supernatants treated
with N-specific siRNAs (Figure 6B). In contrast, viral plaques
were easily detected in the untreated infected control (Figure 6B).
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FIGURE 4 | qRT-PCR analysis of RVFV replication in response to
RVFV-specific siRNA treatment. (A) Ct values of viral RNA amplification
using supernatants from the various treatments; the Ct values of the siRNA
treatments differed significantly from the untreated virus control (P < 0.05).
(B) Illustrates log10 fold reduction in viral titers relative to the untreated virus
control. si605N and si46N treatments show the highest fold-reductions.
Asterisks (∗∗) above horizontal bars compare differences between treatments
and denote significant differences. Fold reductions in viral titers of si605N or
si46N were not different from siPooledN viral titers (P > 0.05).
DISCUSSION
Since the first reported outbreak of RVF in 1931 (Daubney
and Garnham, 1931), RVFV has been associated with periodic
outbreaks of hemorrhagic fever in humans in Africa and the
Arabian Peninsula (Balkhy and Memish, 2003; Anyangu et al.,
2010; Sow et al., 2014; Boushab et al., 2015) with increasing
case fatality rates (Heald, 2012). There is currently no effective
therapy for RVFV infection in humans and animals; attempts
have been made to treat the disease with unproven antiviral
compounds such as ribavirin (Huggins, 1989). However, ribavirin
has been shown to cause serious undesirable side effects
following treatment (Snell, 2001; Scharton et al., 2014). Thus,
current therapies are palliative in order to relieve patients of
the symptoms of the disease. Considering the lack of good
therapeutic approaches for RVF, we aimed at developing effective
therapeutic intervention strategies for RVF. Therefore, this
study was carried out to investigate the potential application of
RNAi as a therapeutic approach to treat RVF in humans and
animals.
We assessed the impact of posttranscriptional siRNA
silencing of the RVFV nucleoprotein and the RNA-dependent
RNA polymerase L on viral replication using an in vitro cell
culture model and the MP12 strain of RVFV. All 4 siRNA
constructs targeting the viral nucleoprotein gene/mRNA
exhibited significant inhibition of RVFV protein expression and
replication. In contrast, si5849L, targeting the viral L polymerase
exhibited no detectable effect on RVFV protein expression
(Figure 2) and viral replication (data not shown). The reason
for the non-inhibition is unknown, and consequently, siRNA
si5849L was not studied further. The RVFV N gene represents
a good target for posttranscriptional RNAi silencing (Scott
et al., 2012) since the gene is highly conserved among all known
strains of RVFV (Sall et al., 1997), including the attenuated
strain MP12 used in this study. Although MP12 is reported to
contain mutations in all 3 of its genome segments (Saluzzo and
Smith, 1990; Ikegami et al., 2015), sequence analysis revealed
the absence of nucleotide mutations in the N gene, indicating
a 100% identity with the parent wild-type virus ZH548 (data
not shown). Similarly, the MP12 N nucleotide sequence has
a high homology with N genes from other wild-type RVFV
isolates such as ZH501 (Rossi and Turell, 1988), SA01 (Miller
et al., 2002), and Kenya 128B-15 (Sang et al., 2010) of 99.59,
97.15, and 97.15%, respectively (data not shown). This strongly
suggests that the siRNA constructs, especially the pooled cocktail
formulation, will have inhibitory effect on wild-type RVFV
strains.
Protein kinase R is a host-encoded interferon response
effector molecule constitutively expressed in mammalian cells.
Upon RVFV infection, it is degraded by the viral non-
structural protein NSs acting to inhibit host anti-viral innate
immune response (Habjan et al., 2009; Ikegami et al., 2009a,b).
Although the MP12 virus encodes attenuated M- and L-segments,
it carries a virulent NSs gene (Billecocq et al., 2008),
thereby retaining the inherent capacity to degrade constitutively
expressed PKR in infected mammalian cells. Thus, we indirectly
examined the inhibitory effect of the N-specific siRNAs
on RVFV replication by assessing the expression of PKR
as a function of RVFV replication. Treatment of infected
cells with the RVFV N-specific siRNAs completely inhibited
degradation of PKR, indicating the effectiveness of the siRNA
constructs at inhibiting viral replication and consequently
NSs activity (Figure 3). In addition, the antiviral effect of
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FIGURE 5 | Flow cytometry analysis of RVFV replication in response to RVFV-specific siRNA treatment. Only background fluorescence is detectable in the
various siRNA treatments in contrast to the intense fluorescence detected in positive gate of the virus-infected control. A cell only control (untreated and uninfected)
is also shown.
FIGURE 6 | Quantitation of RVFV replication by plaque assay. (A) shows titers of viral progeny detected in the supernatants of the various siRNA treatments.
Asterisks (∗∗) directly above the bars indicate significant differences compared to the virus control (P < 0.05). Asterisks (∗∗) above horizontal lines compare
differences between treatments and denote significant differences. (B) Demonstrates inhibition of viral replication using 104-fold dilution of culture supernatants from
the various treatments. In contrast to the untreated virus control, no plaque could be isolated from the supernatants of the siRNA treatments.
the N-specific siRNAs is not attributable to interferon or
interferon response effector molecules, since some studies
were carried out in an interferon deficient cell line, Vero E6
cells.
Using multiple quantitative assays, e.g., qRT-PCR, flow
cytometry and virus plaque assay, we further demonstrated
significant inhibition of MP12 replication following treatment
with the RVFV N-specific siRNAs (Figures 4–6). All N-specific
siRNAs, including the pooled formulation (siPooledN),
significantly reduced virus replication as determined by qRT-
PCR (P < 0.05) (Figure 4A). The levels of viral RNA were
reduced by at least 3 logs in comparison to the untreated
infected control (Figure 4B), with si605N, si46N and siPooledN
exhibiting significantly higher reductions compared to si252N
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and si476N (P < 0.05) (Figure 4B). A similar picture was seen
using flow cytometry analysis, whereby only the untreated virus-
infected control displayed RVFV-specific, positive fluorescence
(Figure 5). All N-specific siRNA treatments did not result in
RVFV protein expression, indicating effective suppression of
viral replication. The above findings were confirmed by virus
plaque assays (Figure 6A) in which the levels of inhibition of
virus replication was quantified. The complete absence of viral
plaques in a 104 dilution of culture supernatants treated with
the N-specific siRNAs (Figure 6B) confirms the efficacy of this
treatment regimen.
The development of resistance by RNA viruses to antiviral
drugs (Hayden and de Jong, 2011) is a global concern in
the fight to prevent potential viral epidemics or pandemics.
RNAi is considered a promising platform for therapeutic drug
development to overcome these challenges. Unlike conventional
therapeutic drugs, antiviral resistance to siRNAs due to single
nucleotide mutations could be easily addressed by redesigning
new constructs or using pooled formulations that target multiple
loci within the mRNA transcript. Once sequence data of a new
emergent strain are available, it is estimated that clinical grade
siRNA products can be produced in as little as 8 weeks if deemed
necessary (Thi et al., 2015). Thus, the application of RNAi as a
therapeutic option for hemorrhagic viral diseases should be given
serious consideration.
The recent outbreak of Ebolavirus in West Africa claimed
the highest number of human lives in the history of Ebolavirus
disease (ECDC, 2014). To combat the disease, several post-
exposure interventions including lipid nanoparticle siRNA
treatment, which has shown 100% protection in rhesus monkeys
against lethal Ebola virus challenge, have been used (Geisbert
et al., 2010; Thi et al., 2015). Although the Ebola siRNA treatment,
at the time, was not fully vetted, the dire circumstances of
the patients inflicted with the lethal disease provided enough
justification for the US Food and Drugs Administration (FDA)
to allow “compassionate use” of the drug to treat Ebola
patients (Grens, 2014; Bishop, 2015). In 2015, the Ebola siRNA
treatment underwent a Phase II clinical study in Ebola virus
disease patients in Sierra Leone, West Africa (Dunning et al.,
2016). In view of the societal, economic, and other disruptions,
which can be associated with outbreaks of hemorrhagic viral
infections in humans (Faburay, 2015; Kupferschmidt, 2015;
Nanyingi et al., 2015), consideration should be given to RNAi
as a therapeutic platform in outbreak situations. In the last
decades, outbreaks of RVF in various countries in Africa,
e.g., Kenya (Nguku et al., 2010), South Africa (Archer et al.,
2013), Mauritania (Sow et al., 2014; Boushab et al., 2015), and
Saudi Arabia (Al-Hazmi et al., 2003; Himeidan et al., 2014),
caused significant human deaths and economic hardships for
farmers.
CONCLUSION
We have demonstrated the feasibility of RVFV nucleoprotein-
specific siRNAs to inhibit RVFV replication, suggesting the utility
of this technology as a potential therapeutic tool for RVFV
infection. In future studies, we plan to assess the antiviral effect
of these siRNAs with wild-type RVFV isolates and in various
experimental animal models including murine, ruminant, and
non-human primates. Furthermore, we might examine co-
administration of siRNAs in conjunction with subunit vaccines;
this approach could provide protection during the period of the
immunity gap before the vaccine provides efficient protection
(Kim et al., 2015). Adopting such a vaccination scheme could
enhance vaccine efficacy and improve the overall efficiency of
RVF vaccination programs.
AUTHOR CONTRIBUTIONS
BF and JR contributed to the conception of the study. BF designed
the siRNAs, developed and optimized the experimental protocols
and performed the experiments. BF and JR analyzed the data and
wrote the manuscript.
FUNDING
This work was supported by grants from the NBAF Transition
Funds provided by the State of Kansas, the Department of
Homeland Security Center of Excellence for Emerging and
Zoonotic Animal Diseases (CEEZAD), Grant No.2010-ST061-
AG001, and Kansas Bioscience Authority.
ACKNOWLEDGMENTS
The authors would like to acknowledge Kansas State NBAF
Transition Fund provided by the State of Kansas, the DHS
Center of Excellence for Emerging and Zoonotic Animal Diseases
(CEEZAD) and the Kansas Bioscience Authority for supporting
this work. We thank BEI Resources, NIH, Manassas, VA, USA,
for providing the RVFV N monoclonal antibody R3-ID8.
REFERENCES
Al-Hazmi, M., Ayoola, E. A., Abdurahman, M., Banzal, S., Ashraf, J., El-Bushra, A.,
et al. (2003). Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe
illness in humans. Clin. Infect. Dis. 36, 245–252. doi: 10.1086/345671
Anyangu, A. S., Gould, L. H., Sharif, S. K., Nguku, P. M., Omolo, J. O.,
Mutonga, D., et al. (2010). Risk factors for severe Rift Valley fever infection
in Kenya, 2007. Am. J. Trop. Med. Hyg. 83, 14–21. doi: 10.4269/ajtmh.2010.
09-0293
Archer, B. N., Thomas, J., Weyer, J., Cengimbo, A., Landoh, D. E., Jacobs, C.,
et al. (2013). Epidemiologic investigations into outbreaks of Rift Valley fever
in humans, South Africa 2008-2011. Emerg. Infect. Dis. 19, 1918–1925. doi:
10.3201/eid1912.121527
Balkhy, H. H., and Memish, Z. A. (2003). Rift valley fever: an uninvited zoonosis
in the Arabian Peninsula. Int. J. Antimicrob. Agents 21, 153–157. doi: 10.1016/
S0924-8579(02)00295-9
Bertrand, J. R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., and Malvy, C.
(2002). Comparison of antisense oligonucleotides and siRNAs in cell culture
Frontiers in Microbiology | www.frontiersin.org 9 November 2016 | Volume 7 | Article 1889
fmicb-07-01889 November 22, 2016 Time: 17:16 # 10
Faburay and Richt Rift Valley Fever Virus Inhibition
and in vivo. Biochem. Biophys. Res. Commun. 296, 1000–1004. doi: 10.1016/
S0006-291X(02)02013-2
Billecocq, A., Gauliard, N., Le May, N., Elliott, R. M., Flick, R., and Bouloy, M.
(2008). RNA polymerase I-mediated expression of viral RNA for the rescue of
infectious virulent and avirulent Rift Valley fever viruses. Virology 378, 377–384.
doi: 10.1016/j.virol.2008.05.033
Billecocq, A., Spiegel, M., Vialat, P., Kohl, A., Weber, F., Bouloy, M., et al. (2004).
NSs protein of Rift Valley fever virus blocks interferon production by inhibiting
host gene transcription. J. Virol. 78, 9798–9806. doi: 10.1128/JVI.78.18.9798-
9806.2004
Bird, B. H., Albariño, C. G., Hartman, A. L., Erickson, B. R., Ksiazek, T. G., and
Nichol, S. T. (2008). Rift valley fever virus lacking the NSs and NSm genes is
highly attenuated, confers protective immunity from virulent virus challenge,
and allows for differential identification of infected and vaccinated animals.
J. Virol. 82, 2681–2691. doi: 10.1128/jvi.02501-07
Bird, B. H., Maartens, L. H., Campbell, S., Erasmus, B. J., Erickson, B. R., Dodd,
K. A., et al. (2011). Rift valley fever virus vaccine lacking the NSs and NSm
genes is safe, nonteratogenic, and confers protection from viremia, pyrexia,
and abortion following challenge in adult and pregnant sheep. J. Virol. 85,
12901–12909. doi: 10.1128/jvi.06046-11
Bishop, B. M. (2015). Potential and emerging treatment options for Ebola virus
disease. Ann. Pharmacother. 49, 196–206. doi: 10.1177/1060028014561227
Bouloy, M., Janzen, C., Vialat, P., Khun, H., Pavlovic, J., Huerre, M., et al. (2001).
Genetic evidence for an interferon-antagonistic function of Rift Valley fever
virus nonstructural protein NSs. J. Virol. 75, 1371–1377. doi: 10.1128/JVI.75.
3.1371-1377.2001
Boushab, M. B., Savadogo, M., Sow, M. S., Fall-Malick, F. Z., and Seydi, M. (2015).
[Severe hemorrhagic form of Rift Valley fever in mauritania]. Bull. Soc. Pathol.
Exot. 108, 102–106. doi: 10.1007/s13149-015-0417-y
Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). Stable suppression of
tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243–247.
doi: 10.1016/S1535-6108(02)00122-8
Caplen, H., Peters, C. J., and Bishop, D. H. (1985). Mutagen-directed attenuation
of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66,
2271–2277. doi: 10.1099/0022-1317-66-10-2271
Daubney, R., and Garnham, P. (1931). Enzootic hepatitis or Rift Valley fever. An
undescribed virus disease of sheep, cattle and man from East Africa. J. Pathol.
Bacteriol. 34, 545–579. doi: 10.1002/path.1700340418
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., et al. (2016).
Experimental treatment of Ebola Virus disease with TKM-130803: a single-
arm phase 2 clinical trial. PLoS Med. 13:e1001997. doi: 10.1371/journal.pmed.
1001997
ECDC (2014). European Center for Disease Prevention and Control. Outbreak of
Ebola Virus Disease in West Africa. Stockholm: ECDC.
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T.
(2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured
mammalian cells. Nature 411, 494–498. doi: 10.1038/35078107
Faburay, B. (2015). The case for a ‘one health’ approach to combating vector-borne
diseases. Infect. Ecol. Epidemiol. 5, 28132.
Faburay, B., Lebedev, M., McVey, D. S., Wilson, W., Morozov, I., Young, A.,
et al. (2014). A glycoprotein subunit vaccine elicits a strong Rift Valley fever
virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis. 14,
746–756. doi: 10.1089/vbz.2014.1650
Faburay, B., Wilson, W., McVey, D. S., Drolet, B. S., Weingartl, H., Madden, D.,
et al. (2013). Rift Valley fever virus structural and nonstructural proteins:
recombinant protein expression and immunoreactivity against antisera from
sheep. Vector Borne Zoonotic Dis. 13, 619–629. doi: 10.1089/vbz.2012.1285
Faburay, B., Wilson, W. C., Gaudreault, N. N., Davis, A. S., Shivanna, V., Bawa, B.,
et al. (2016). A recombinant Rift Valley fever virus glycoprotein subunit vaccine
confers full protection against Rift Valley fever challenge in sheep. Sci. Rep. 6,
27719. doi: 10.1038/srep27719
Flick, R., and Bouloy, M. (2005). Rift Valley fever virus. Curr. Mol. Med. 5, 827–834.
doi: 10.2174/156652405774962263
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V.,
et al. (2010). Postexposure protection of non-human primates against a lethal
Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet
375, 1896–1905. doi: 10.1016/s0140-6736(10)60357-1
Gerrard, S., Bird, B., Albarino, C., and Nichol, S. (2007). The NSm proteins of
Rift Valley fever virus are dispensable for maturation, replication and infection.
Virology 359, 459–465. doi: 10.1016/j.virol.2006.09.035
Gerrard, S. R., and Nichol, S. T. (2007). Synthesis, proteolytic processing and
complex formation of N-terminally nested precursor proteins of the Rift Valley
fever virus glycoproteins. Virology 357, 124–133. doi: 10.1016/j.virol.2006.08.
002
Gitlin, L., Karelsky, S., and Andino, R. (2002). Short interfering RNA confers
intracellular antiviral immunity in human cells. Nature 418, 430–434. doi: 10.
1038/nature00873
Grens, K. (2014). FDA OKs siRNA Ebola Drug. TheScientist. Available at: http://
www.the-scientist.com/?articles.view/articleNo/41081/title/FDA-OKs-siRNA-
Ebola-Drug/
Haasnoot, J., and Berkhout, B. (2006). RNA interference: its use as antiviral therapy.
Handb. Exp. Pharmacol. 173, 117–150. doi: 10.1007/3-540-27262-3_7
Haasnoot, P. C., Cupac, D., and Berkhout, B. (2003). Inhibition of virus replication
by RNA interference. J. Biomed. Sci. 10, 607–616. doi: 10.1007/BF02256311
Habjan, M., Pichlmair, A., Elliott, R. M., Overby, A. K., Glatter, T., Gstaiger, M.,
et al. (2009). NSs protein of Rift Valley fever virus induces the specific
degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83,
4365–4375. doi: 10.1128/jvi.02148-08
Hayden, F. G., and de Jong, M. D. (2011). Emerging influenza antiviral resistance
threats. J. Infect. Dis. 203, 6–10. doi: 10.1093/infdis/jiq012
Heald, R. (2012). Infectious disease surveillance update: Rift Valley fever
in Mauritania. Lancet Infect. Dis. 12, 915. doi: 10.1016/S1473-3099(12)
70305-5
Himeidan, Y. E., Kweka, E. J., Mahgoub, M. M., El Rayah el, A., and Ouma, J. O.
(2014). Recent outbreaks of Rift Valley fever in East Africa and the middle East.
Front. Public Health 2:169. doi: 10.3389/fpubh.2014.00169
Huggins, J. W. (1989). Prospects for treatment of viral hemorrhagic fevers with
ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4),
S750–S761. doi: 10.1093/clinids/11.Supplement_4.S750
Ikegami, T. (2012). Molecular biology and genetic diversity of Rift Valley fever
virus. Antiviral Res. 95, 293–310. doi: 10.1016/j.antiviral.2012.06.001
Ikegami, T., Hill, T. E., Smith, J. K., Zhang, L., Juelich, T. L., Gong, B., et al. (2015).
Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination
of partial attenuations in the S, M, and L segments. J. Virol. 89, 7262–7276.
doi: 10.1128/jvi.00135-15
Ikegami, T., and Makino, S. (2011). The pathogenesis of Rift Valley fever. Viruses 3,
493–519. doi: 10.3390/v3050493
Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C. J., and Makino, S.
(2009a). Dual functions of Rift Valley fever virus NSs protein: inhibition of host
mRNA transcription and post-transcriptional downregulation of protein kinase
PKR. Ann. N. Y. Acad. Sci. 1171(Suppl. 1), E75–E85. doi: 10.1111/j.1749-6632.
2009.05054.x
Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C. J., and Makino, S.
(2009b). Rift Valley fever virus NSs protein promotes post-transcriptional
downregulation of protein kinase PKR and Inhibits eIF2α phosphorylation.
PLoS Pathog. 5:e1000287. doi: 10.1371/journal.ppat.1000287
Ikegami, T., Won, S., Peters, C., and Makino, S. (2006). Rescue of infectious Rift
Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene,
and expression of a foreign gene. J. Virol. 80, 2933–2940. doi: 10.1128/JVI.80.6.
2933-2940.2006
Jouan, A., Coulibaly, I., Adam, F., Philippe, B., Riou, O., Leguenno, B., et al.
(1989). Analytical study of a Rift Valley fever epidemic. Res. Virol. 140, 175–186.
doi: 10.1016/S0923-2516(89)80096-2
Kim, S. M., Park, J. H., Lee, K. N., Kim, S. K., You, S. H., Kim, T., et al. (2015).
Robust protection against highly virulent foot-and-mouth disease virus in swine
by combination treatment with recombinant adenoviruses expressing porcine
alpha and gamma interferons and multiple small interfering RNAs. J. Virol. 89,
8267–8279. doi: 10.1128/jvi.00766-15
Kupferschmidt, K. (2015). Surviving Ebola survival. Science 348, 1406–1407. doi:
10.1126/science.348.6242.1406
LaBeaud, A. D., Pfeil, S., Muiruri, S., Dahir, S., Sutherland, L. J., Traylor, Z., et al.
(2015). Factors associated with severe human Rift Valley fever in Sangailu,
Garissa County, Kenya. PLoS Negl. Trop. Dis. 9:e0003548. doi: 10.1371/journal.
pntd.0003548
Frontiers in Microbiology | www.frontiersin.org 10 November 2016 | Volume 7 | Article 1889
fmicb-07-01889 November 22, 2016 Time: 17:16 # 11
Faburay and Richt Rift Valley Fever Virus Inhibition
Le May, N., Dubaele, S., De Santis, L. P., Billecocq, A., Bouloy, M., and Egly, J.-M.
(2004). TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever
virus. Cell 116, 541–550. doi: 10.1016/s0092-8674(04)00132-1
Le May, N., Mansuroglu, Z., Leger, P., Josse, T., Blot, G., Billecocq, A., et al.
(2008). A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus
infected cells. PLoS Pathog. 4:e13. doi: 10.1371/journal.ppat.0040013
Mandell, R. B., and Flick, R. (2010). Rift Valley fever virus: an unrecognized
emerging threat? Hum. Vaccin. 6, 597–601. doi: 10.4161/hv.6.7.11761
Medarova, Z., Pham, W., Farrar, C., Petkova, V., and Moore, A. (2007). In vivo
imaging of siRNA delivery and silencing in tumors. Nat. Med. 13, 372–377.
doi: 10.1038/nm1486
Miller, B. R., Godsey, M. S., Crabtree, M. B., Savage, H. M., Al-Mazrao, Y., Al-Jeffri,
M. H., et al. (2002). Isolation and genetic characterization of Rift Valley fever
virus from Aedes vexans arabiensis, Kingdom of Saudi Arabia. Emerg. Infect.
Dis. 8, 1492–1494. doi: 10.3201/eid0812.020194
Nanyingi, M. O., Munyua, P., Kiama, S. G., Muchemi, G. M., Thumbi, S. M.,
Bitek, A. O., et al. (2015). A systematic review of Rift Valley fever epidemiology
1931-2014. Infect. Ecol. Epidemiol. 5, 28024. doi: 10.3402/iee.v5.28024
Nguku, P. M., Sharif, S. K., Mutonga, D., Amwayi, S., Omolo, J., Mohammed, O.,
et al. (2010). An investigation of a major outbreak of Rift Valley fever in
Kenya: 2006-2007.Am. J. Trop.Med. Hyg. 83, 5–13. doi: 10.4269/ajtmh.2010.09-
0288
Rossi, C. A., and Turell, M. J. (1988). Characterization of attenuated strains of Rift
Valley fever virus. J. Gen. Virol. 69(Pt 4), 817–823. doi: 10.1099/0022-1317-69-
4-817
Sall, A. A., de, A. Z. P. M., Zeller, H. G., Digoutte, J. P., Thiongane, Y., and
Bouloy, M. (1997). Variability of the NS(S) protein among Rift Valley fever
virus isolates. J. Gen. Virol. 78(Pt 11), 2853–2858. doi: 10.1099/0022-1317-78-
11-2853
Saluzzo, J. F., and Smith, J. F. (1990). Use of reassortant viruses to map attenuating
and temperature-sensitive mutations of the Rift Valley fever virus MP-12
vaccine. Vaccine 8, 369–375. doi: 10.1016/0264-410X(90)90096-5
Sang, R., Kioko, E., Lutomiah, J., Warigia, M., Ochieng, C., O’Guinn, M., et al.
(2010). Rift Valley fever virus epidemic in Kenya, 2006/2007: the entomologic
investigations. Am. J. Trop. Med. Hyg. 83, 28–37. doi: 10.4269/ajtmh.2010.09-
0319
Scharton, D., Bailey, K. W., Vest, Z., Westover, J. B., Kumaki, Y., Van Wettere, A.,
et al. (2014). Favipiravir (T-705) protects against peracute Rift Valley fever virus
infection and reduces delayed-onset neurologic disease observed with ribavirin
treatment. Antiviral Res. 104, 84–92. doi: 10.1016/j.antiviral.2014.01.016
Schwentker, F. F., and Rivers, T. M. (1934). RIFT VALLEY FEVER IN MAN
: REPORT OF A FATAL LABORATORY INFECTION COMPLICATED BY
THROMBOPHLEBITIS. J. Exp. Med. 59, 305–313. doi: 10.1084/jem.59.3.305
Scott, T., Paweska, J. T., Arbuthnot, P., and Weinberg, M. S. (2012). Pathogenic
effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by
expressed antiviral short hairpin RNAs. Antivir. Ther. 17, 643–656. doi: 10.
3851/imp2073
Shoemaker, T., Boulianne, C., Vincent, M. J., Pezzanite, L., Al-Qahtani, M. M., Al-
Mazrou, Y., et al. (2002). Genetic analysis of viruses associated with emergence
of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg. Infect. Dis. 8,
1415–1420. doi: 10.3201/eid0812.020195
Snell, N. J. (2001). Ribavirin–current status of a broad spectrum antiviral agent.
Expert Opin. Pharmacother. 2, 1317–1324. doi: 10.1517/14656566.2.8.1317
Sow, A., Faye, O., Ba, Y., Ba, H., Diallo, D., Loucoubar, C., et al. (2014). Rift Valley
fever outbreak, southern Mauritania, 2012. Emerg. Infect. Dis. 20, 296–299.
doi: 10.3201/eid2002.131000
Thi, E. P., Mire, C. E., Lee, A. C., Geisbert, J. B., Zhou, J. Z., Agans, K. N., et al.
(2015). Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected
nonhuman primates. Nature 521, 362–365. doi: 10.1038/nature14442
Won, S., Ikegami, T., Peters, C. J., and Makino, S. (2007). NSm protein of Rift
Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81, 13335–13345.
doi: 10.1128/JVI.01238-07
Xia, H., Mao, Q., Eliason, S. L., Harper, S. Q., Martins, I. H., Orr, H. T., et al.
(2004). RNAi suppresses polyglutamine-induced neurodegeneration in a model
of spinocerebellar ataxia. Nat. Med. 10, 816–820. doi: 10.1038/nm1076
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Faburay and Richt. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 11 November 2016 | Volume 7 | Article 1889
